Drug name - Baxdela
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9539250 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(3 years from now) | |
| US8273892 | MELINTA | Salt and crystalline forms thereof of a drug |
Aug, 2026
(3 years from now) | |
| US7728143 | MELINTA | Salt and crystalline forms thereof of a drug |
Nov, 2027
(5 years from now) | |
| US8871938 | MELINTA | Process for making quinolone compounds |
Sep, 2029
(6 years from now) | |
| USRE46617 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(7 years from now) | |
| CN102164912A | MELINTA | Process For Preparing Quinolone Compounds |
Sep, 2029
(6 years from now) | |
| CN102164912B | MELINTA | Preparing Process Of Quinolones Compound |
Sep, 2029
(6 years from now) | |
| IN201101315P2 | MELINTA | Process For Making Quinolone Compounds |
Sep, 2029
(6 years from now) | |
| IN290385B | MELINTA | Process For Making Quinolone Compounds |
Sep, 2029
(6 years from now) | |
| EP3056492A1 | MELINTA | Meglumine Salt And Crystalline Forms Thereof Of A Drug (Delafloxacin) |
Oct, 2025
(3 years from now) | |
| EP3056492B1 | MELINTA | Meglumine Salt And Crystalline Forms Thereof Of A Drug (Delafloxacin) |
Oct, 2025
(3 years from now) | |
| EP2346855A4 | MELINTA | Process For Making Quinolone Compounds |
Sep, 2029
(6 years from now) | |
| EP2346855B1 | MELINTA | Process For Making Quinolone Compounds |
Sep, 2029
(6 years from now) | |
| EP2346855A2 | MELINTA | Process For Making Quinolone Compounds |
Sep, 2029
(6 years from now) | |
| EP3214083B1 | MELINTA | Process For Making Quinolone Compounds |
Sep, 2029
(6 years from now) | |
| EP3214083A1 | MELINTA | Process For Making Quinolone Compounds |
Sep, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8969569 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(3 years from now) | |
| US8648093 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(3 years from now) | |
| US8252813 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2026
(3 years from now) | |
| US9750822 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US8410077 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US9200088 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US7635773 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US9493582 | MELINTA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(10 years from now) | |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 450MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.